These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 19922995)

  • 1. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
    Konstam MA; Neaton JD; Dickstein K; Drexler H; Komajda M; Martinez FA; Riegger GA; Malbecq W; Smith RD; Guptha S; Poole-Wilson PA;
    Lancet; 2009 Nov; 374(9704):1840-8. PubMed ID: 19922995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment.
    Hu DY; Huang J; Cai NS; Zhu WL; Li YS; Massaad R; Hanson ME; Dickstein K
    Chin Med J (Engl); 2012 Nov; 125(21):3868-74. PubMed ID: 23106890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study.
    Rossignol P; Girerd N; Gregory D; Massaro J; Konstam MA; Zannad F
    Int J Cardiol; 2015; 187():183-9. PubMed ID: 25828348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
    Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
    Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial.
    Kiernan MS; Wentworth D; Francis G; Martinez FA; Dickstein K; Komajda M; Zannad F; Neaton JD; Konstam MA
    Eur J Heart Fail; 2012 Dec; 14(12):1401-9. PubMed ID: 23187648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.
    Rossignol P; Dobre D; Gregory D; Massaro J; Kiernan M; Konstam MA; Zannad F
    Int J Cardiol; 2014 May; 173(3):380-7. PubMed ID: 24726210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    Axelsson A; Iversen K; Vejlstrup N; Ho C; Norsk J; Langhoff L; Ahtarovski K; Corell P; Havndrup O; Jensen M; Bundgaard H
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):123-31. PubMed ID: 25533774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure.
    Kiernan MS; Gregory D; Sarnak MJ; Rossignol P; Massaro J; Kociol R; Zannad F; Konstam MA
    JACC Heart Fail; 2015 Mar; 3(3):214-23. PubMed ID: 25742759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R
    J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G;
    Lancet; 2008 Oct; 372(9645):1223-30. PubMed ID: 18757090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
    Patel AN; Henry TD; Quyyumi AA; Schaer GL; Anderson RD; Toma C; East C; Remmers AE; Goodrich J; Desai AS; Recker D; DeMaria A;
    Lancet; 2016 Jun; 387(10036):2412-21. PubMed ID: 27059887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
    Pitt B; Poole-Wilson PA; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
    Lancet; 2000 May; 355(9215):1582-7. PubMed ID: 10821361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of treatment with losartan vs candesartan and mortality among patients with heart failure.
    Svanström H; Pasternak B; Hviid A
    JAMA; 2012 Apr; 307(14):1506-12. PubMed ID: 22496265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
    Pitt B; Segal R; Martinez FA; Meurers G; Cowley AJ; Thomas I; Deedwania PC; Ney DE; Snavely DB; Chang PI
    Lancet; 1997 Mar; 349(9054):747-52. PubMed ID: 9074572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.